Examples of using Crizotinib in Swedish and their translations into English
{-}
-
Colloquial
-
Official
-
Medicine
-
Ecclesiastic
-
Ecclesiastic
-
Official/political
-
Computer
-
Programming
-
Political
Hur fungerar Crizotinib pulver?
Varje hård kapsel innehåller 200 mg crizotinib.
Each hard capsule contains 200 mg crizotinib.Crizotinib hämmar OCT1 och OCT2 in vitro.
Crizotinib is an inhibitor of OCT1 and OCT2 in vitro.Den aktiva substansen i XALKORI är crizotinib.
The active substance in XALKORI is crizotinib.Crizotinib kan tas med
Crizotinib can be administered withApprovals och indikationer för Crizotinib pulver.
Approvals and indications for Crizotinib powder.Crizotinib visade inga teratogena effekter hos dräktiga råttor eller kaniner.
Crizotinib was not shown to be teratogenic in pregnant rats or rabbits.Karcinogenicitetsstudier med crizotinib har inte utförts.
Carcinogenicity studies with crizotinib have not been performed.Ämnen vars plasmakoncentration kan förändras av crizotinib.
Agents whose plasma concentrations may be altered by crizotinib.In vitro-studier tyder på att crizotinib hämmar CYP2B6.
In vitro studies indicated that crizotinib is an inhibitor of CYP2B6.Crizotinib har dock inte studerats hos personer med nedsatt leverfunktion.
However, crizotinib has not been studied in patients with hepatic impairment.Publicerat 06/11/2018 by Dr Patrick Young skrev i Crizotinib.
Posted on 06/11/2018 by Dr. Patrick Young wrote in Crizotinib.En in vitro-studie har visat att crizotinib kan hämma intestinalt P-gp.
Based on an in vitro study, crizotinib is predicted to inhibit intestinal P-gp.Mindre än 0, 5% av patienterna drabbades av febril neutropeni i kliniska studier med crizotinib.
Less than 0.5% of patients experienced febrile neutropenia in clinical studies with crizotinib.In vitro hämmar crizotinib inte BSEP vid kliniskt relevanta koncentrationer.
In vitro, crizotinib is not an inhibitor of BSEP at clinically relevant concentrations.Mindre än 0, 5% av patienterna har drabbats av febril neutropeni i kliniska studier med crizotinib.
Less than 0.5% of patients experienced febrile neutropenia in clinical studies with crizotinib.I kliniska studier med crizotinib rapporterades fall med gastrointestinal perforation.
In clinical studies with crizotinib, events of gastrointestinal perforations were reported.kan förekomma hos patienter som får crizotinib.
can occur in patients receiving crizotinib.In vitro-studier har visat att crizotinib är en svag hämmare av UGT1A1
In vitro studies showed that crizotinib is a weak inhibitor of UGT1A1Bradykardi oavsett orsak rapporterades i kliniska studier hos 13% av patienterna som behandlades med crizotinib.
All-causality bradycardia was reported in clinical studies in 13% of patients treated with crizotinib.Noggrann övervakning rekommenderas när crizotinib administreras med läkemedel som är P-gp-substrat.
Close clinical surveillance is recommended when crizotinib is administered with these medicinal products.Antingen ALK-positiv eller ROS1-positiv NSCLC-status ska fastställas innan behandling med crizotinib påbörjas.
Either ALK-positive or ROS1-positive NSCLC status should be established prior to initiation of crizotinib therapy.Bindningen av crizotinib till humana plasmaproteiner in vitro är 91%
Binding of crizotinib to human plasma proteins in vitro is 91%av 1722 patienter behandlade med crizotinib.
out of 1722 patients treated with crizotinib.Samtidig administrering av crizotinib och starka CYP3A-hämmare kan öka plasmakoncentrationen av crizotinib. .
Coadministration of crizotinib with strong CYP3A inhibitors may increase Intrakraniell sjukdomskontroll(IC-DCR) vecka 12 var 65% och 46% för crizotinib- respektive kemoterapibehandlade patienter.
Intracranial Disease Control Rate(IC-DCR) at 12 weeks was 65% and 46% for crizotinib and chemotherapy-treated patients, respectively.Eftersom crizotinib metaboliseras i hög utsträckning i levern,
As crizotinib is extensively metabolized in the liver,Av 172 ALK-positiva patienter behandlade med crizotinib i den randomiserade fas 3-studien 1007 var 27(16%)
Of 172 ALK-positive patients treated with crizotinib in randomised Phase 3 Study 1007,Användning av crizotinib som enda läkemedel vid behandling av ROS1-positiv avancerad NSCLC undersöktes i en multinationell enarmad multicenterstudie, studie 1001.
The use of single-agent crizotinib in the treatment of ROS1-positive advanced NSCLC was investigated in multicenter, multinational, single-arm Study 1001.Dock observerades ingen induktion in vivo när crizotinib samtidigt administrerades med CYP3A4-probsubstratet midazolam.
However, there was no observed induction in vivo when crizotinib was coadministered with the CYP3A probe substrate midazolam.
